key: cord-0758562-heiqcd94
authors: Bai, Zhaofang; Li, Pengyan; Wen, Jincai; Han, Yanzhong; Cui, Yuanyuan; Zhou, Yongfeng; Shi, Zhuo; Chen, Shuaishuai; Li, Qiang; Zhao, Xu; Wang, Zhongxia; Li, Ruisheng; Guo, Yuming; Zhan, Xiaoyan; Xu, Guang; Ding, Kaixin; Wang, Jiabo; Xiao, Xiaohe
title: Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury
date: 2021-11-14
journal: J Ethnopharmacol
DOI: 10.1016/j.jep.2021.114838
sha: 52e7e13e9df880cadda75a7d37d0999c0db015aa
doc_id: 758562
cord_uid: heiqcd94

ETHNOPHARMACOLOGICAL RELEVANCE: Keguan-1, a new traditional Chinese medicine (TCM) prescription contained seven Chinese herbs, is developed to treat coronavirus disease 19 (COVID-19). The first internationally registered COVID-19 randomised clinical trial on integrated therapy demonstrated that Keguan-1 significantly reduced the incidence of ARDS and inhibited the severe progression of COVID-19. AIM OF THE STUDY: To investigate the protective mechanism of Keguan-1 on ARDS, a lipopolysaccharide (LPS)-induced acute lung injury (ALI) model was used to simulate the pathological state of ARDS in patients with COVID-19, focusing on its effect and mechanism on ALI. MATERIALS AND METHODS: Mice were challenged with LPS (2 mg/kg) by intratracheal instillation (i.t.) and were orally administered Keguan-1 (low dose, 1.25 g/kg; medium dose, 2.5 g/kg; high dose, 5 g/kg) after 2 h. Bronchoalveolar lavage fluid (BALF) and lung tissue were collected 6 h and 24 h after i.t. LPS administration. The levels of inflammatory factors tumour necrosis factor α (TNF-α), interleukin (IL)-6, IL-1β, keratinocyte-derived chemokine (KC or mCXCL1), macrophage inflammatory protein 2 (MIP2 or mCXCL2), angiotensin II (Ang II), and endothelial cell junction-associated proteins were analysed using ELISA or western blotting. RESULTS: Keguan-1 improved the survival rate, respiratory condition, and pathological lung injury; decreased the production of proinflammatory factors (TNF-α, IL-6, IL-1β, KC, and MIP2) in BALF and the number of neutrophils in the lung tissues; and ameliorated inflammatory injury in the lung tissues of the mice with LPS-induced ALI. Keguan-1 also reduced the expression of Ang II and the adhesion molecule ICAM-1; increased tight junction proteins (JAM-1 and claudin-5) and VE-cadherin expression; and alleviated pulmonary vascular endothelial injury in LPS-induced ALI. CONCLUSION: These results demonstrate that Keguan-1 can improve LPS-induced ALI by reducing inflammation and pulmonary vascular endothelial injury, providing scientific support for the clinical treatment of patients with COVID-19. Moreover, it also provides a theoretical basis and technical support for the scientific use of TCMs in emerging infectious diseases.

severe patients could develop ARDS characterized by dyspnea and low blood oxygen saturation, which may further progress into multiple organ failure, or even death 75 (Karmakar et al., 2021; B. . Currently, the treatment for ARDS is 76 relatively limited. If the disease progresses to a severe stage, the mortality rate might 77 reach as high as 40% -70% (Tay et al., 2020) . The key to COVID-19 management is 78 to prevent the occurrence of ARDS and to control the disease progression from mild to 79 severe. 80 COVID-19 has emerged as a pandemic and public health crisis due to a lack of 81 specific antiviral drugs and vaccinations for treatment and prevention. Traditional 

The anal temperature was recorded using an anal thermometer. For the blood gas 179 analysis, blood was drawn from the abdominal aorta, anticoagulated with heparin 180 lithium, and investigated using a blood gas analyser (Epoc blood analysis, USA). anaesthesia. The trachea was exposed and cannulated using a 22-gauge angiocatheter.

Both the lungs were lavaged with three separate 0.5 mL volumes of ice-cold phosphate 209 buffered saline (PBS). The BALF was centrifuged at 420 × g for 10 min at 4°C to pellet appropriate horseradish peroxidase-conjugated secondary antibodies and were then visualised using an enhanced chemiluminescence reagent (Millipore, Massachusetts, 250 USA). Image J software was used for gray value analysis. GAPDH was used as internal 251 control to calculate the gray scale ratio for each protein band in relation to internal 252 control bands. All data are shown as the mean ± SEM or the mean ± SD. Statistical comparisons 255 were performed using an unpaired, 2-tailed t-test between the two groups. One-way 256 ANOVA, followed by least significant difference (LSD) post hoc test, was used to 257 assess the differences of multi-groups with GraphPad Prism 8.4.2 (GraphPad Software).

Statistical significance was set at P < 0.05. with Keguan-1 alleviated these effects (Fig. 2) . These results suggest that Keguan-1 has 297 a protective effect against ALI. (E) in the BALF. The data are presented as the mean ± SEM. ## P < 0.01 and ### P < 0.001 vs. control; * P 320 < 0.05, ** P < 0.01, and *** P < 0.001 vs. LPS group. 321 Keguan-1 treatment reduced the number of Ly6G + neutrophils that infiltrated the lung 330 tissue (Fig. 4A, B) . Thereafter, we examined whether Keguan-1 decreased alveolar using flow cytometry for F4/80 (macrophages), Annexin V (apoptotic and necrotic 333 cells), and 7AAD (necrotic cells). The results showed that after Keguan-1 treatment, 334 alveolar macrophage necrosis significantly decreased in the LPS-induced ALI mouse 335 model (Fig. 4D) . Consistent with this finding, the level of IL-1α in BALF was 336 attenuated by treatment with Keguan-1 (Fig. 4C) , suggesting a positive role of Keguan-337 1 in alleviating the lung injury induced by LPS. 

Rapid establishment of 601 traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical 602 experience and molecular docking

Protective effects of aerobic exercise on acute lung 607 injury induced by LPS in mice

Traditional Chinese medicine for COVID-19 treatment

Alveolar 611 macrophage-derived microvesicles mediate acute lung injury

The trinity of COVID-19: immunity, 614 inflammation and intervention

Endothelial cell infection and endotheliitis in 618 COVID-19

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

Pathogenesis and management of myocardial 629 injury in coronavirus disease 2019

Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia 634 in Wuhan, China

Epidemiological and 648 clinical features of the 2019 novel coronavirus outbreak in China

Clinical 651 characteristics of 82 cases of death from COVID-19

SARS-CoV-2 binds 655 platelet ACE2 to enhance thrombosis in COVID-19

SARS-CoV-2 binds 659 platelet ACE2 to enhance thrombosis in COVID-19

Compound edaravone alleviates lipopolysaccharide (LPS)-induced acute lung injury in 663 mice

Systems pharmacological study illustrates the immune 666 regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei

Du decoction in the treatment of COVID-19

Tang facilitates ovarian function through improving ovarian microenvironment and 671 angiogenesis in a mouse model of premature ovarian failure